

# Invitation to presentation of Xbrane Biopharma's interim report January-September 2019 on November 15, 2019

**Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on November 15th, 2019, at 10.00 a.m. CET. Xbrane will publish the company's interim report for the period January-September 2019, on Friday November 15th, 2019, at 8.00 a.m. CET.**

Martin Åmark, CEO, and Susanna Helgesen, CFO, will present Xbrane and comment on the interim report for the period January-September 2019, followed by a Q&A session. The presentation will be in English. To attend, please dial-in at one of the numbers below:

Standard international: +44 (0) 2071 928 000

UK (Local): +44 (0) 844 571 88 92

UK (Toll free): 08 003 767 922

Sweden (Local): +46 (0) 850 692 180

Sweden (Toll free): 020 012 55 81

US (Local): +1 631 510 74 95

US (Toll free): +1 866 966 13 96

Confirmation Code: 73 79 585

**Web link:**

<https://edge.media-server.com/mmc/p/qbduqx4h>

**Contacts**

---

Martin Åmark, CEO

M: +46 (0) 763-093 777

E: [martin.amark@xbrane.com](mailto:martin.amark@xbrane.com)

Susanna Helgesen, CFO

M: +46 (0) 708-278 636

E: [susanna.helgesen@xbrane.com](mailto:susanna.helgesen@xbrane.com)

## About Us

---

*Xbrane is a commercial phase Swedish biopharmaceutical company that develop and produces biosimilars. Xbrane has a patented protein production platform for development of biosimilars and world leading expertise in biosimilars. Xbrane's headquarter is located in Solna outside of Stockholm and the company's in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq Stockholm since September 2019 with the ticker XBRANE. For more information please visit [www.xbrane.com](http://www.xbrane.com).*

## Attachments

---

[Invitation to presentation of Xbrane Biopharma's interim report January-September 2019 on November 15, 2019](#)